TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

BACKGROUND: Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntavatzikos, Anastasios, Spathis, Aris, Patapis, Paul, Machairas, Nikolaos, Vourli, Georgia, Peros, George, Papadopoulos, Iordanis, Panayiotides, Ioannis, Koumarianou, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657223/
https://www.ncbi.nlm.nih.gov/pubmed/31367274
http://dx.doi.org/10.4251/wjgo.v11.i7.551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657223/
https://www.ncbi.nlm.nih.gov/pubmed/31367274
http://dx.doi.org/10.4251/wjgo.v11.i7.551

Ejemplares similares